Your analysis makes good sense with clear rationality. In particular, the impact of GLP-1s on Obstructive Sleep Apnea (OSA) and subsequently on ResMed’s volumes is a core uncertainty for the years ahead. However, I remain confident that there are much more penetrations of continuous positive airway pressure (CPAP) therapy to people in developed and developing countries in particular.
Having noted the impact of GLP-1s on RMD share price, the price goes up and up as we are worrying and writing.
Looking at RSI (14 & 30 days line) technical indications, it is not in overbought territory yet.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$38.59 |
Change
-0.010(0.03%) |
Mkt cap ! $22.45B | |||
| Open | High | Low | Value | Volume |
| $38.50 | $38.72 | $38.43 | $25.63M | 664.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2665 | $38.51 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $38.62 | 1526 | 2 |
View Market Depth
| Last trade - 16.10pm 17/06/2025 (20 minute delay) ? |
| RMD (ASX) Chart |